Octave Bioscience, a company focused on delivering precision medicine for neurodegenerative diseases like multiple sclerosis, announced it closed a $30 million extension to its Series B round.
Hikma Pharmaceuticals' venture capital arm, Hikma Ventures, participated in the round alongside Novartis (dRx Capital) and Intermountain Ventures. Existing investors Echo Health Ventures, Deerfield...
